Day 1 – Wednesday 3rd May
09:00 LSX Welcome Address
Caitlin McNally, Conference Director- Medtech Lead, LSX
09:10 Keynote Presentation: Defining The Future Of Medtech
Jennifer Joe, Chair, MMS
09:30 Keynote Panel: Back To Reality – Reflecting On M&A Activity In The Medtech Market
Medtech offers a lucrative market for investors. With high barriers to entry, increasingly sophisticated technological innovations, and a host of clinical and nonclinical unmet needs to address, the industry looks set for years of profitable growth. The supercharged year of 2021 may have raised the expectations of some, and a quieter medtech market begs the question why pharma companies have achieved more value-creating growth than medtech companies? Additionally, why has medtech M&A not kept pace with industry growth overall? A panel of industry strategists discuss the challenges faced and the expected growth and pace of medtech M&A in the coming years.
10:15 Morning Break
11:10 Panel: Invested In Investment – A 360° Scrutiny Of Global Funding In The Medtech ArenaYear in, year out the goals for investment remain largely the same. Attracting funding and investment is absolutely vital for long term success of a company and fundraising needs to be considered from the moment of company creation, and front of mind throughout its lifecycle from thereon in. Raising funds can be a slow process and an investment securement strategy and investor relationship building is critical. How do companies know when to close and approach another round of funding? Layered with geographical differences, it can be a complex process for medtech companies worldwide. A panel of global medtech investors discuss the trends of medtech investment and how companies can prepare to secure the capital they need to continue development.
12:00 Panel: Realising The American Dream – Taking Advantage Of The US Market
The US has replaced the Europe as the priority market for medical device companies, with an approximate of 89% of European medtech companies planning to prioritise FDA authorisation going forward. The lack of a common market in Europe alongside regulatory challenges are some of those pinpointed as the cause. However, the route to market in the US is no mean feat and challenges remain for medtech companies in the US medtech industry. The past few years have seen regulators on both sides of the Atlantic change their approach to Medtech. The biggest changes are occurring in Europe, where MDR and IVDR are redefining what it takes to bring products to market in the region. At the same time, the FDA has set the target of making the US the priority market for developers of novel devices. A panel of experts discuss what medtech companies need to consider when trying to break America.
12:50 Lunch Break
14:00 Panel: Navigating Challenges Medtech’s Next Era – Investment, Regulation And Strategic M&A
Gunnar Sachs, Partner, Clifford Chance
14:50 Panel: Missing In Medtech – A Spotlight On The Underserved Clinical Markets
With ongoing digital transformation of the industry, the medtech arena is poised now, more than ever, to strive towards innovation in areas of unmet clinical need. Unmet medical needs should help to shape policy and action from early phase research through clinical development, to pricing and reimbursement and how a new medical device is used in practice. But how research and health care communities define and quantify unmet medical need is challenging, and how medtech companies begin to address them even more so. A panel of key leaders discuss how medtech companies can tackle healthcare challenges.
Catherine Boule, Managing Partner, Karista
Ishani Malhotra, CEO, Carcinotech
Nnamdi Njoku, SVP & President, Neuromodulation, Medtronic
15:40 Afternoon Break
16:20 Panel: Improving Market Access Strategies Across Europe
Although the second largest market for medical devices in the world, being a complex fragmented market coupled with the challenge of changing regulations paints a difficult landscape in Europe for those without deep pockets. The concern is these challenges may reduce the availability or access of innovative treatments for European patients. Though many medtech companies have made it across the finish line, the question is - how? A panel of experts discuss the current situation in Europe and how medtech companies can navigate the tricky waters of market access.
17:00 Panel: Peeling Back The Layers – The True Value Of A Medtech Device
The Medtech market is saturated with products promising to be the next best thing, but are they technical masterpieces without the clinical pay-off? A panel of experts discuss the role of product design in ensuring a product is truly valuable to the payer, the common mistakes in product development, and how companies can truly meet clinical needs.
17:40 Drinks Reception
18:30 Networking Party
Day 2 – Thursday 4th May
09:00 LSX Welcome Address
Caitlin McNally, Conference Director - Medtech Lead, LSX
09:15 Keynote Panel: Where Do We Go From Here? Marking A New Era In Medtech
The last few tumultuous years have uprooted and shaken the medtech industry, and the opportunities of a new era have arrived. The pandemic shone a bright light on the critical role of medical technology in delivering effective functioning of the health care system. The future of health is expected to be driven by an integrated system of health and well-being, with transformational technologies playing a large role. When it comes to medtech, we expect medical devices to combine hardware and software to allow customers to diagnose and perhaps even treat medical conditions at home. The potential to redesign the healthcare system is clear, but what role will the Medtech industry play? How will the lines blur with biotech and healthtech as we anticipate the possibility of a holistic healthcare system?
Ori Hadomi, VP, Strategic Initiatives & Partnerships, Medtronic
Wilfred Van Zuilen, President EMEA, Zimmer Biomet
10:15 Morning Break
11:10 Panel: Holistic And Patient-Centric – Digitisation Of Medtech And The Future Of Care
With an increasingly overburdened healthcare system and a rising prevalence of chronic disease worldwide, where do medical devices fit in the grand scheme of care? Digital transformation has seen medtech companies adopting digital technologies as a core part of their approach to approve patient outcomes as devices become ever more integrated. But what role can medical devices play in the shift towards intervention, preventive and integrated care models, and how is this reconciled with a highly specialised healthcare system?
Benjamin Hertzog, CEO, Intelligent Implants
Erwin Keeve, Professor of Surgical Navigation & Robotics, Charité
Thomas Hummel, Head of Digital Transformation, Fresenius Kabi
12:00 Panel: Jumping Through Hoops - Managing Regulatory Hurdles
Having been in application approaching two years, medtech companies across Europe have seen a considerable backlog of applications to notified bodies, expiring certificates and removal of CE Marks. Although the relevant authorities have highlighted strong concerns regarding the new regulations, for the foreseeable, they are here to stay. A panel of key leaders discuss how medtech companies can navigate the new regulatory landscape and the unexpected benefits a harsher regulatory landscape may bring.
12:50 Lunch Break
14:00 Panel: Funding A-Z – A Roadmap To Approaching Investment In 2023 And Beyond
The rush of ‘COVID cash’ and new investors in the healthcare arena provided entrepreneurs ample supply of funding and high valuations. Now, the buzz has quietened to a hum and lower valuations, and more selective investments, have ushered in a steadier funding landscape. Some medtech companies may be struggling to maintain the momentum generated by the pandemic, whilst newer faces in the industry may be having a tougher time attracting investment overall. A panel of medtech investors discuss how best to approach and attract investment across a company’s lifecycle.
14:40 Panel: Trialling New Methods – Clinical Trial Design
Whilst being the foundation of successful development of medical devices and diagnostics, executing successful clinical trials is always complicated. Having come to a standstill during the pandemic and with reallocation of medical resource, the healthcare system is now thoroughly over-burdened. Stricter regulatory environments mean that medtech companies need to consider now, more than ever, how they design their clinical trials. A panel of industry experts discuss how medtech companies can plan to achieve success and why clinical trial design needs to move with the times.
15:20 Panel: In Pursuit Of ESG – Are You Incinerating Profit?
The healthcare industry leaves a heavy footprint on our climate. With the push for ESG priorities across every industry, sustainability should be moving up the priority ladder within the medtech community. Many companies have yet to meaningfully address their contributions to climate change. The sector needs to revisit business models and develop new ESG strategies to keep a competitive edge, but how companies can practically implement or benefit from ESG policies remains elusive. A panel of key players across the industry discuss why ESG is not only ethical, but lucrative.
Eileen Buckley, VP, Corporate Responsibility and ESG Strategy, Stryker
Natalia Kozmina, EVP, CHRO & ESG Stewardship, Convatec
Nicholas Ibery, Partner, NLC Technology Ventures, Certified B-corp & SFDR-9 Impact Investor
Anila Prahbu, VP of Sustainability, 3M
16:00 Close of Congress